Base de dados : MEDLINE
Pesquisa : C06.552.380.350 [Categoria DeCS]
Referências encontradas : 5282 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 529 ir para página                         

  1 / 5282 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455951
[Au] Autor:Tu T; Bühler S; Bartenschlager R
[Ad] Endereço:.
[Ti] Título:Chronic viral hepatitis and its association with liver cancer.
[So] Source:Biol Chem;398(8):817-837, 2017 07 26.
[Is] ISSN:1437-4315
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Chronic infection with hepatitis viruses represents the major causative factor for end-stage liver diseases, including liver cirrhosis and primary liver cancer (hepatocellular carcinoma, HCC). In this review, we highlight the current understanding of the molecular mechanisms that drive the hepatocarcinogenesis associated with chronic hepatitis virus infections. While chronic inflammation (associated with a persistent, but impaired anti-viral immune response) plays a major role in HCC initiation and progression, hepatitis viruses can also directly drive liver cancer. The mechanisms by which hepatitis viruses induce HCC include: hepatitis B virus DNA integration into the host cell genome; metabolic reprogramming by virus infection; induction of the cellular stress response pathway by viral gene products; and interference with tumour suppressors. Finally, we summarise the limitations of hepatitis virus-associated HCC model systems and the development of new techniques to circumvent these shortcomings.
[Mh] Termos MeSH primário: Hepatite Crônica/complicações
Neoplasias Hepáticas/complicações
[Mh] Termos MeSH secundário: Animais
Carcinoma Hepatocelular/complicações
Carcinoma Hepatocelular/metabolismo
Carcinoma Hepatocelular/patologia
Carcinoma Hepatocelular/virologia
Hepacivirus/genética
Hepacivirus/metabolismo
Hepacivirus/fisiologia
Vírus da Hepatite B/genética
Vírus da Hepatite B/metabolismo
Vírus da Hepatite B/fisiologia
Seres Humanos
Neoplasias Hepáticas/metabolismo
Neoplasias Hepáticas/patologia
Neoplasias Hepáticas/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  2 / 5282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28953614
[Au] Autor:Barragué H; Condat B; Petitdidier N; Champagne E; Renou C; Izopet J; Abravanel F
[Ad] Endereço:aCentre de Physiopathologie de Toulouse Purpan, INSERM U1043/CNRS UMR5282/Université Toulouse III Paul-Sabatier, Toulouse bHôpital Sainte Camille, Bry sur Marne cDivision of Hepatology, Centre Hospitalier de Hyères, Hyères dCentre Hospitalier Universitaire de Toulouse, Hôpital Purpan, Laboratoire de virologie, Centre National de Référence Hépatite E, Institut fédératif de biologie de Purpan, Toulouse, France.
[Ti] Título:Chronic hepatitis E virus infection in a cirrhotic patient: A case report.
[So] Source:Medicine (Baltimore);96(39):e7915, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Acute hepatitis E virus (HEV) infections are usually self-limiting in immunocompetent patients. HEV persistence has been described only in immunosuppressed patients such as solid-organ transplant recipients, patients with hematological diseases, or patients with human immunodeficiency virus (HIV) infection. PATIENT CONCERNS: A 61-year-old patient was admitted in hospital for jaundice and asthenia. DIAGNOSES: The patient had underlying cirrhosis and developed a chronic HEV infection. INTERVENTION: Ribavirin therapy was initiated. OUTCOMES: Ribavirin therapy for 12 months allowed the clearance of the virus and HEV viral load remained undetectable thereafter. This patient had taken no immunosuppressive drugs, was not suffering from any autoimmune disease and was not infected with HIV. We studied the patient's anti-HEV immune response months after the viral clearance. His peripheral blood mononuclear cells (PBMC) were stimulated in vitro by HEV peptides. The patient had a mild T lymphopenia, but polyclonal stimulation of PBMC showed a robust T cell response. The response of his anti-HEV specific interferon-γ producing T cells was low. LESSONS: Other studies are now needed to identify the population with a chronic evolution of HEV infection despite no apparent immunodepression.
[Mh] Termos MeSH primário: Antivirais/uso terapêutico
Hepatite E/complicações
Hepatite E/tratamento farmacológico
Cirrose Hepática/complicações
Ribavirina/uso terapêutico
[Mh] Termos MeSH secundário: ELISPOT
Hepatite E/imunologia
Hepatite Crônica/complicações
Hepatite Crônica/tratamento farmacológico
Hepatite Crônica/imunologia
Seres Humanos
Interferon gama/sangue
Cirrose Hepática/imunologia
Cirrose Hepática/virologia
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 49717AWG6K (Ribavirin); 82115-62-6 (Interferon-gamma)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007915


  3 / 5282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28850969
[Au] Autor:Sauerbruch T; Schierwagen R; Trebicka J
[Ti] Título:[Statins as a Therapy of Chronic Liver Disease?]
[Ti] Título:Statine als Therapie bei Lebererkrankungen?.
[So] Source:Dtsch Med Wochenschr;142(17):1313-1318, 2017 Sep.
[Is] ISSN:1439-4413
[Cp] País de publicação:Germany
[La] Idioma:ger
[Ab] Resumo:Statins have proven effects in the primary and secondary prevention of coronary disease. Besides lowering LDL-cholesterol beneficial pleiotropic consequences of statin therapy are increasingly discussed. Retrospective analyses of large cohort studies have shown favorable effects on the sequels of chronic viral induced liver disease and of non alcoholic fatty liver disease. These findings are substantiated by experimental work showing that statins reduce inflammation, fibrosis and proliferation in the diseased liver. Prospective controlled trials are necessary to elucidate whether, when and where statins have a role in the therapeutic armamentarium for liver disease.
[Mh] Termos MeSH primário: Hepatite Crônica
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Hepatopatia Gordurosa não Alcoólica
[Mh] Termos MeSH secundário: Doença Crônica
Hepatite Crônica/tratamento farmacológico
Hepatite Crônica/fisiopatologia
Seres Humanos
Hepatopatia Gordurosa não Alcoólica/tratamento farmacológico
Hepatopatia Gordurosa não Alcoólica/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170830
[St] Status:MEDLINE
[do] DOI:10.1055/s-0043-114682


  4 / 5282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28692371
[Au] Autor:Shahid S; Rait S; Sharples E; Gorard D
[Ad] Endereço:Gastroenterology Registrar, Gastroenterology Office, Wycombe Hospital, Buckinghamshire Healthcare NHS Trust, High Wycombe HP11 2TT.
[Ti] Título:Chronic hepatitis in the transplant patient.
[So] Source:Br J Hosp Med (Lond);78(7):408-409, 2017 Jul 02.
[Is] ISSN:1750-8460
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Rejeição de Enxerto/prevenção & controle
Hepatite E/diagnóstico
Hepatite Crônica/diagnóstico
Imunossupressores/efeitos adversos
Transplante de Rim
Doenças Renais Policísticas/cirurgia
[Mh] Termos MeSH secundário: Idoso
Alanina Transaminase/sangue
Antivirais/uso terapêutico
Hepatite E/sangue
Hepatite E/tratamento farmacológico
Hepatite E/etiologia
Vírus da Hepatite E/genética
Vírus da Hepatite E/imunologia
Hepatite Crônica/sangue
Hepatite Crônica/tratamento farmacológico
Hepatite Crônica/etiologia
Seres Humanos
Hospedeiro Imunocomprometido
Imunoglobulina M/sangue
Masculino
Ácido Micofenólico/efeitos adversos
Reação em Cadeia da Polimerase
RNA Viral/sangue
Ribavirina/uso terapêutico
Tacrolimo/efeitos adversos
Carga Viral
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Immunoglobulin M); 0 (Immunosuppressive Agents); 0 (RNA, Viral); 49717AWG6K (Ribavirin); EC 2.6.1.2 (Alanine Transaminase); HU9DX48N0T (Mycophenolic Acid); WM0HAQ4WNM (Tacrolimus)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170711
[St] Status:MEDLINE
[do] DOI:10.12968/hmed.2017.78.7.408


  5 / 5282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28428284
[Au] Autor:Nguyen Canh H; Harada K; Ouchi H; Sato Y; Tsuneyama K; Kage M; Nakano M; Yoshizawa K; Takahashi A; Abe M; Kang JH; Koike K; Inui A; Fujisawa T; Takaki A; Arinaga-Hino T; Torimura T; Suzuki Y; Fujiwara K; Zeniya M; Ohira H; Tanaka A; Takikawa H; Intractable Liver and Biliary Diseases Study Group of Japan
[Ad] Endereço:Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
[Ti] Título:Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients.
[So] Source:J Clin Pathol;70(11):961-969, 2017 Nov.
[Is] ISSN:1472-4146
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIMS: Although liver biopsy is crucial to diagnose and guide treatment decisions, a detailed histological analysis of autoimmune hepatitis (AIH) with clinically acute presentations has not yet been performed. This study aimed to characterise the histological features and explore potential histological hallmarks to diagnose the acute presentation of AIH. METHODS: We systematically evaluated liver specimens of 87 adult patients with acute presentation of AIH retrospectively enrolled from Japanese multicentre facilities. Each histological feature was predefined by consensus based on the diagnostic criteria. RESULTS: Key findings were that acute presentation of AIH revealed histological features of both acute hepatitis and chronic hepatitis accompanying various degrees of fibrosis. The prominent features were lobular necrosis/inflammation (97.7%), plasma cell infiltration (96.4%), emperipolesis (89.3%), pigmented macrophages (84.5%), cobblestone appearance of hepatocytes (82.6%) and perivenular necroinflammatory activity, including centrilobular necrosis (81.4%). CONCLUSIONS: The acute presentation of AIH represents the entire histological spectrum of acute hepatitis and chronic hepatitis with various activity grades and fibrosis stages that clinically correspond to acute-onset AIH and acute exacerbation of classic AIH, respectively. Although there are no pathognomonic features for the pathological diagnosis, the prominent presence of lobular and perivenular necroinflammatory activity, pigmented macrophages and cobblestone appearance of hepatocytes in addition to the classic AIH features, such as plasma cell infiltration and emperipolesis, are useful for the pathological diagnosis of the acute presentation of AIH.
[Mh] Termos MeSH primário: Hepatite Autoimune/patologia
Hepatite Crônica/patologia
Cirrose Hepática/patologia
Fígado/patologia
[Mh] Termos MeSH secundário: Doença Aguda
Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Biópsia
Feminino
Hepatócitos/patologia
Seres Humanos
Japão
Macrófagos/patologia
Masculino
Meia-Idade
Necrose
Plasmócitos/patologia
Valor Preditivo dos Testes
Estudos Retrospectivos
Índice de Gravidade de Doença
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170422
[St] Status:MEDLINE
[do] DOI:10.1136/jclinpath-2016-204271


  6 / 5282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28376032
[Au] Autor:Mazzola A; Tran Minh M; Charlotte F; Hdiji A; Bernard D; Wendum D; Calmus Y; Conti F
[Ad] Endereço:1 APHP, Hôpital Pitié-Salpêtrière, Unité Médicale de Transplantation Hépatique, Hépato-Gastro-Enterologie. Hôpital Pitié-Salpêtrière UPMC Paris VI, Boulevard de l'Hôpital, Paris, France. 2 Medicina Traslazionale, Università Piemonte Orientale Amedeo Avogrado, Italy. 3 APHP, Hôpital Pitié-Salpêtrière, Service d'Anatomie et Cytologie Pathologique, Paris, France. 4 APHP, Hôpital Pitié-Salpêtrière, Service d'Anesthésie-Réanimation, Paris, France. 5 APHP, Hôpital Saint Antoine, Service d'Anatomie et Cytologie Pathologique, Paris, France.
[Ti] Título:Chronic Hepatitis E Viral Infection After Liver Transplantation: A Regression of Fibrosis After Antiviral Therapy.
[So] Source:Transplantation;101(9):2083-2087, 2017 Sep.
[Is] ISSN:1534-6080
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hepatitis E virus (HEV) infection is increasingly being reported in immunocompromised patients and particularly organ transplant recipients. In this context, HEV infection frequently evolves to chronic infection with a rapid progression of fibrosis to cirrhosis. Ribavirin monotherapy and a minimization of immunosuppression represent the treatment of choice, with a good response rate. However, no data are available on whether treatment can achieve a regression of liver fibrosis in chronic HEV patients. A 57-year-old male patient received a liver transplant for alcoholic cirrhosis and, 6 years later, developed biopsy-proven chronic HEV infection. The patient received different antiviral therapy regimens (pegylated interferon alpha 2b and ribavirin different dosages, and long-term treatment with ribavirin monotherapy still ongoing) but without achieving a sustained virological response. Liver function parameters normalized after 1 month of treatment but without the clearance of HEV. Hepatitis E virus RNA levels also remained detectable in the serum and stools throughout ribavirin monotherapy. No serious adverse events were reported. A gradual regression of liver fibrosis was reported (Metavir A0/F1 in 2015 versus A3/F4 in 2008). Long-term treatment with ribavirin is safe in liver transplant recipients, without achieving HEV sustained virological response, and may induce a biopsy-proven regression of liver fibrosis in a liver transplant recipient with cirrhosis after chronic HEV infection.
[Mh] Termos MeSH primário: Antivirais/uso terapêutico
Hepatite E/tratamento farmacológico
Hepatite Crônica/tratamento farmacológico
Cirrose Hepática/tratamento farmacológico
Transplante de Fígado/efeitos adversos
Infecções Oportunistas/tratamento farmacológico
[Mh] Termos MeSH secundário: Biópsia
Quimioterapia Combinada
Hepatite E/diagnóstico
Hepatite E/imunologia
Hepatite E/virologia
Hepatite Crônica/diagnóstico
Hepatite Crônica/imunologia
Hepatite Crônica/virologia
Seres Humanos
Hospedeiro Imunocomprometido
Imunossupressores/efeitos adversos
Cirrose Hepática/diagnóstico
Cirrose Hepática/imunologia
Cirrose Hepática/virologia
Masculino
Meia-Idade
Infecções Oportunistas/diagnóstico
Infecções Oportunistas/imunologia
Infecções Oportunistas/virologia
Indução de Remissão
Resposta Viral Sustentada
Terapêutica
Fatores de Tempo
Carga Viral
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Immunosuppressive Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170405
[St] Status:MEDLINE
[do] DOI:10.1097/TP.0000000000001766


  7 / 5282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28355956
[Au] Autor:Stefansdottir J; Christensen E; Schiødt FV
[Ad] Endereço:a Digestive Disease Center K, Section of Medical Gastroenterology , Bispebjerg Hospital, Copenhagen, University of Copenhagen , Copenhagen NV , Denmark.
[Ti] Título:Hepatocellular carcinoma in Danish patients: a single Copenhagen center experience.
[So] Source:Scand J Gastroenterol;52(6-7):768-772, 2017 Jun - Jul.
[Is] ISSN:1502-7708
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Hepatocellular carcinoma (HCC) is a common cause of cancer, and most HCC patients have underlying cirrhosis. Retrospectively, we aimed to characterize patients with newly diagnosed HCC at a Danish hospital and to investigate survival and identify predictive factors for survival. METHODS: All patients diagnosed with HCC from January 2008 to December 2014 were retrospectively enrolled in this study. Overall survival was estimated by using the Kaplan-Meier method. A multivariate Cox regression analysis was performed to identify predictive factors for survival. RESULTS: Sixty-seven patients were diagnosed with HCC (incidence rate 3.55/100,000 people/year). Ninety-three percent had underlying cirrhosis. Alcohol-related liver disease and chronic viral hepatitis B or C were responsible for 55 and 31% of cases, respectively. Median survival was 81 days and 1-month, 3-months and 1-year cumulative survival rates were 74, 40 and 17%, respectively. We identified the presence of portal vein thrombosis, high Child-Pugh score, high MELD score and high AST as independent negative prognostic factors for survival. Survival was poorer in patients seen for the first time when the diagnosis of HCC was made than in patients followed in the outpatient clinic (p = .06) indicating a substantial delay in diagnosis. CONCLUSIONS: Survival was poor in this cohort of patients, almost exclusively caused by delay in diagnosis and admittance to hospital. An increased general information about HCC and the possibilities of therapy seems warranted.
[Mh] Termos MeSH primário: Carcinoma Hepatocelular/diagnóstico
Cirrose Hepática/complicações
Neoplasias Hepáticas/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Carcinoma Hepatocelular/patologia
Carcinoma Hepatocelular/terapia
Dinamarca
Feminino
Hepatite Crônica/complicações
Seres Humanos
Hepatopatias Alcoólicas/complicações
Neoplasias Hepáticas/patologia
Neoplasias Hepáticas/terapia
Imagem por Ressonância Magnética
Masculino
Meia-Idade
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons
Estudos Retrospectivos
Análise de Sobrevida
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170331
[St] Status:MEDLINE
[do] DOI:10.1080/00365521.2017.1304985


  8 / 5282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28347321
[Au] Autor:Chinese Journal of Cancer
[Ti] Título:The 150 most important questions in cancer research and clinical oncology series: questions 6-14 : Edited by Chinese Journal of Cancer.
[So] Source:Chin J Cancer;36(1):33, 2017 Mar 27.
[Is] ISSN:1944-446X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:To accelerate our endeavors to overcome cancer, Chinese Journal of Cancer has launched a program of publishing 150 most important questions in cancer research and clinical oncology. In this article, nine more questions are presented as followed. Question 6. Why do nasopharyngeal carcinomas rarely metastasize to the brain? Question 7. Can distant spread of cancer cells be blocked by inhibiting the remodeling of high endothelial venules in the sentinel lymph node? Question 8. What sort of live-imaging techniques can be developed to directly observe the dynamic processes of metastasis? Question 9. How does chronic hepatitis prevent liver metastasis from colorectal cancer? Question 10. How many types of host cells contribute to forming the pre-metastatic niche in the lung favorable for metastasis? Question 11. Why do cancers rarely metastasize to the small bowel? Question 12. Why do glioblastomas rarely metastasize outside the central nervous system? Question 13. Despite increased understanding of the molecular genetic events leading to the development and progression of high-grade gliomas, these tumors are the most therapeutically refractory among all human cancers. What then would be the most effective therapeutic approaches to treat what in essence can be regarded as a whole brain malignancy, since even a surgical resection of greater than 99% of tumor tissues is invariably associated with recurrence? Question 14. The blood-brain barrier (BBB) effectively limits a wide variety of potential therapeutic agents from reaching glioma cells widely dispersed in the brain. What therapeutic approaches can be used to breach the BBB and allow therapeutic agents to seek out and kill these tumor cells?
[Mh] Termos MeSH primário: Neoplasias Colorretais/patologia
Hepatite Crônica/complicações
Neoplasias Nasofaríngeas/patologia
[Mh] Termos MeSH secundário: Neoplasias Encefálicas/secundário
Movimento Celular
Seres Humanos
Neoplasias Hepáticas/secundário
Oncologia
Fatores de Risco
[Pt] Tipo de publicação:EDITORIAL
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170329
[St] Status:MEDLINE
[do] DOI:10.1186/s40880-017-0200-0


  9 / 5282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28330722
[Au] Autor:Lin TH; Yen HR; Chiang JH; Sun MF; Chang HH; Huang ST
[Ad] Endereço:Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan ROC; School of Chinese Medicine, China Medical University, Taichung, Taiwan ROC.
[Ti] Título:The use of Chinese herbal medicine as an adjuvant therapy to reduce incidence of chronic hepatitis in colon cancer patients: A Taiwanese population-based cohort study.
[So] Source:J Ethnopharmacol;202:225-233, 2017 Apr 18.
[Is] ISSN:1872-7573
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:ETHNOPHARMACOLOGICAL RELEVANCE: There is a decided lack of in-depth studies to evaluate the effectiveness of Chinese Herbal Medicine (CHM) as an adjuvant therapy on the incidence of chronic hepatitis in patients with colon cancer. AIM OF THE STUDY: The aim of this study is to assess whether CHM treatment decreased the incidence of chronic hepatitis in colon cancer patients who received conventional Western medical treatment. MATERIALS AND METHODS: A Taiwanese nationwide population-based study of colon cancer patients receiving Western medicine treatment in conjunction with CHM treatment, using data provided by the National Health Insurance (NHI) Research Database, was conducted. A total of 61676 patients were diagnosed with colon cancer in Taiwan within the defined study period, from 1997 to 2010. After randomly equal matching for age, sex, excluding patients younger than 18 years of age, chronic hepatitis before colon cancer diagnosis date, receiving acupuncture and/or moxibustion and taking CHM for less than 30 days, data from 155 patients were analyzed. Hazard ratios of incidence rate of chronic hepatitis were used to determine the influence of CHM and the therapeutic potential of herbal products in treating patients with colon cancer. RESULTS: CHM used for patients with colon cancer exhibited significantly decreased incidence rates of chronic hepatitis [hazard ratio (HR)=0.53; 95% confidence interval (CI):0.38-0.74], with multivariate adjustment, compared to those without CHM use. The protective effect of CHM treatment with statistical significance across the stratification of age, gender, co-morbidity and treatment modality was noted. The cumulative incidence of chronic hepatitis was also reduced in patients with colon cancer receiving CHM treatment during a five-year period. In this study, we provide the ten most used single herbs and herbal formulas that were prescribed for patients with colon cancer; moreover, we identify the eight single herbs and five formulas used in CHM treatment which significantly decreased incidence of chronic hepatitis among colon cancer patients. CONCLUSIONS: This nationwide retrospective cohort study determined that therapy using CHM as an adjuvant modality may have a significant impact on liver protection in patients with colon cancer.
[Mh] Termos MeSH primário: Neoplasias do Colo/complicações
Terapias Complementares/estatística & dados numéricos
Medicamentos de Ervas Chinesas/uso terapêutico
Hepatite Crônica/tratamento farmacológico
Hepatite Crônica/etiologia
Medicina Tradicional Chinesa
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Estudos de Coortes
Neoplasias do Colo/epidemiologia
Uso de Medicamentos
Feminino
Hepatite Crônica/epidemiologia
Seres Humanos
Incidência
Masculino
Meia-Idade
População
Estudos Retrospectivos
Fatores Socioeconômicos
Taiwan/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drugs, Chinese Herbal)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170324
[St] Status:MEDLINE


  10 / 5282 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28295621
[Au] Autor:Sakamoto Y; Sakai M; Watari T
[Ad] Endereço:Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan.
[Ti] Título:Hepatic and Plasma Endothelin-1 in Dogs with Chronic Hepatitis.
[So] Source:J Vet Intern Med;31(3):764-769, 2017 May.
[Is] ISSN:1939-1676
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Endothelin (ET)-1 is a 21-amino-acid peptide with potent vasoactive properties, which increases intrahepatic resistance in patients with chronic hepatitis (CH) or cirrhosis. ET-1 concentrations have not been investigated in dogs with CH. HYPOTHESIS/OBJECTIVES: This study compared hepatic and plasma ET-1 levels in healthy dogs and in dogs with CH, and examined the relationship between the plasma ET-1 level and portal vein pressure in dogs with CH. ANIMALS: Fourteen healthy dogs and twenty dogs with CH were used in this study. METHODS: Prospective case-control study. Hepatic ET-1 mRNA expression was determined by real-time reverse transcription polymerase chain reaction, and hepatic and plasma ET-1 levels were assessed using ELISA. Splenic pulp pressure (SPP), as an indicator of portal vein pressure, was measured laparoscopically. RESULTS: Hepatic ET-1 mRNA levels were 3.7 times higher in dogs with CH than in healthy dogs (P = .008). The median hepatic and plasma ET-1 protein levels were significantly higher in dogs with CH than in healthy dogs (13.20 pg/mg wet liver vs. 3.42 pg/mg wet liver, P = .004, and 0.99 pg/mL vs. 0.71 pg/mL, P = .013, respectively). Moreover, there was a weak but significant correlation between plasma ET-1 level and SPP in dogs with CH (P = .036; r = 0.53). CONCLUSIONS AND CLINICAL IMPORTANCE: The results indicate that ET-1 might play an important role in the pathogenesis of portal hypertension caused by CH.
[Mh] Termos MeSH primário: Doenças do Cão/metabolismo
Endotelina-1/metabolismo
Hepatite Crônica/veterinária
[Mh] Termos MeSH secundário: Animais
Estudos de Casos e Controles
Doenças do Cão/sangue
Cães
Endotelina-1/sangue
Feminino
Hepatite Crônica/metabolismo
Masculino
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Endothelin-1)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.1111/jvim.14687



página 1 de 529 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde